Bailard Inc. purchased a new stake in Epizyme Inc (NASDAQ:EPZM) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $251,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Fox Run Management L.L.C. bought a new stake in shares of Epizyme during the third quarter worth about $223,000. JGP Global Gestao de Recursos Ltda. bought a new stake in shares of Epizyme during the third quarter worth about $292,000. Teacher Retirement System of Texas bought a new stake in shares of Epizyme during the fourth quarter worth about $202,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Epizyme during the third quarter worth about $459,000. Finally, Trexquant Investment LP increased its position in shares of Epizyme by 134.3% during the third quarter. Trexquant Investment LP now owns 28,593 shares of the biopharmaceutical company’s stock worth $545,000 after acquiring an additional 16,387 shares in the last quarter. 82.95% of the stock is owned by hedge funds and other institutional investors.
Epizyme Inc (NASDAQ:EPZM) opened at $18.15 on Tuesday. Epizyme Inc has a twelve month low of $9.30 and a twelve month high of $20.45. The firm has a market cap of $1,260.00, a PE ratio of -8.00 and a beta of 2.19.
In related news, COO Matthew Ros sold 72,264 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the transaction, the chief operating officer now directly owns 74,867 shares in the company, valued at $1,245,038.21. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 25.20% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was published by BBNS and is the property of of BBNS. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://baseballnewssource.com/markets/bailard-inc-purchases-shares-of-20000-epizyme-inc-epzm/1890582.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.